Accueil   Diary - News   All news Mablink Bioscience, the next generation ADC company, raises €4 Million from a syndicate of private investors

Mablink Bioscience, the next generation ADC company, raises €4 Million from a syndicate of private investors

Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs

 

 

Lyon, France, April 27, 2021 - Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlinkTM platform, announces today the completion of a €4 Million Seed financing round led by Elaia Partners and along with Pertinence Invest 2 (Sofimac Innovation advised by Mérieux Equity Partners), Sham Innovation Santé (advised by Turenne Capital), Fondation Fournier-Majoie, Simba Santé (Angelor) and Crédit Agricole Création.

 

Transforming the field of ADC to treat cancers with high unmet medical needs

 

ADC is a new class of drugs that work like a guided missile: a monoclonal antibody is used to transport physically linked highly potent cytotoxic molecules directly and specifically into the tumor cells to destroy them, while sparing healthy tissues. Leveraging its proprietary PSARlinkTM technology that links cytotoxic molecules to antibodies, Mablink Bioscience aims at transforming the field of ADC by both multiplying their clinical therapeutic index and by broadening the spectrum of usable compounds, addressable targets and indications they can apply to. Mablink Bioscience will use the proceeds of this financing round to move forward its ADC pipeline directed against several cancers with high unmet medical needs.

 

 

Read the press release